Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Golimumab by Johnson & Johnson for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
Golimumab is under clinical development by Johnson & Johnson and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes)....
Data Insights
Golimumab by Johnson & Johnson for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Golimumab is under clinical development by Johnson & Johnson and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According...